Journal article
Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma
Abstract
The International Extranodal Lymphoma Study Group-32 (IELSG32) randomized patients with primary central nervous system lymphoma (PCNSL) for induction treatment with methotrexate-cytarabine, methotrexate-cytarabine-rituximab, or methotrexate-cytarabine-thiotepa-rituximab (MATRix) and reported significantly improved complete remission with the MATRix regimen. This study assessed cost-effectiveness among these three induction strategies for PCNSL. …
Authors
Beca JM; Raza K; Mow E; Keech J; Kouroukis CT
Journal
Leukemia & Lymphoma, Vol. 61, No. 5, pp. 1097–1107
Publisher
Taylor & Francis
Publication Date
April 15, 2020
DOI
10.1080/10428194.2020.1711902
ISSN
1042-8194